Publications by authors named "Ji-Yong Gong"
Article Synopsis
- - Lung cancer is the most common cancer and a major cause of cancer deaths in China, prompting a study to assess the direct medical costs associated with its care from 2002 to 2011.
- - The study analyzed data from 15,437 patients across 13 provinces, revealing that the average medical expenditure per lung cancer case in 2011 was 39,015 CNY (about US$6,041), with a 7.55% annual increase over the period.
- - Drug costs constituted the largest share of medical expenses at 54.27%, with treatment and surgical costs following behind; costs varied significantly depending on regional factors and hospital types.
Article Synopsis
- * The average age of diagnosis was 59.3 years, with a notable rise in stage IV diagnoses from 13.5% to 20.5% over the study period; also, there was a shift toward more advanced diagnostic technologies such as CT and MRI, while x-ray usage decreased.
- * Surgical treatments declined, with more patients receiving chemotherapy; average medical costs per patient rose significantly from about 47,259 to 86,709 Chinese
Article Synopsis
- This study examined the health-related quality of life (HRQoL) of colorectal precancer and cancer patients in China, using data collected from a cross-sectional survey conducted from 2012 to 2014 across 12 provinces.* -
- A total of 376 precancer and 2,470 CRC patients participated, with utility scores indicating a significant decline in HRQoL compared to the general population, particularly noting pain and discomfort as major issues.* -
- Multivariate analysis identified various factors influencing utility scores including treatment type, education, income, and geographic location, suggesting the need for tailored interventions and further evaluations in healthcare.*
Article Synopsis
- Stomach cancer is a significant health issue in China, ranking as the third most common cancer and a leading cause of cancer deaths, prompting a study on the medical expenses related to treatment.
- A study involving 14,692 patients revealed that medical expenses for the first course of treatment increased from an average of around 20,000 CNY in 2002 to about 43,249 CNY (6851 USD) in 2011, marking an annual increase of 7.4%.
- The rising costs are primarily attributed to longer hospital stays and more treatment episodes, with drug expenses comprising over half of the total medical costs.
Article Synopsis
- - This study investigates liver cancer medical costs in urban China from 2002 to 2011, revealing a significant rise in average treatment expenses from ¥21,950 to ¥40,386 over the decade.
- - An analysis of 12,342 patients shows that pharmaceutical expenses constitute the largest portion of costs, rising from 48.01% to 52.96%, while nursing fees remain minimal at about 1%.
- - The findings indicate that liver cancer imposes a heavy economic burden on families, with early diagnosis and treatment potentially reducing costs; expenditures are notably higher in the eastern region compared to the west and central areas.
Background: Esophageal cancer is associated with substantial disease burden in China, and data on the economic burden are fundamental for setting priorities in cancer interventions. The medical expenditure for the diagnosis and treatment of esophageal cancer in China has not been fully quantified. This study aimed to examine the medical expenditure of Chinese patients with esophageal cancer and the associated trends.
View Article and Find Full Text PDFAim: We aimed to assess economic burden of breast cancer (BC) diagnosis and treatment in China through a multicenter cross-sectional study, and to obtain theoretical evidence for policy-making.
Methods: This survey was conducted in 37 hospital centers across 13 provinces in China from September 2012 to December 2014. We collected information on the subject characteristics.
Background: The increasing prevalence of colorectal cancer (CRC) in China and the paucity of information about relevant expenditure highlight the necessity of better understanding the financial burden and effect of CRC diagnosis and treatment. We performed a survey to quantify the direct medical and non-medical expenditure as well as the resulting financial burden of CRC patients in China.
Methods: We conducted a multicenter, cross-sectional survey in 37 tertiary hospitals in 13 provinces across China between 2012 and 2014.
Objective: To observe the protection effect of Ligustrazine Hydrochloride (LH) on coagulation reaction and inflammation reaction in single valve replacement patients with rheumatic heart disease undergoing cardiopulmonary bypass (CPB).
Methods: Totally 40 patients undergoing single valve replacement were recruited in the study and randomly assigned to the two groups, the treatment group and the control group, 20 in each group. In treatment group LH (3 mg/kg) was intravenously infused from the jugular vein.